SHR6390 at a dose of
PreclinicalSmall molecule
SHR6390 at a dose of is one of 18 small molecule programs targeting Breast Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Adenocard
AstellasPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Acupan
YYonsei University
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Promestriene
UUniversity of Sao Paulo General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR6390 at a dose of. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShengjing Hospital